SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-214901
Filing Date
2020-08-10
Accepted
2020-08-10 16:02:55
Documents
14
Period of Report
2020-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d51957d8k.htm   iXBRL 8-K 25688
2 EX-99.1 d51957dex991.htm EX-99.1 68053
6 GRAPHIC g51957g78j81.gif GRAPHIC 1813
  Complete submission text file 0001193125-20-214901.txt   226940

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20200810.xsd EX-101.SCH 3052
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20200810_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20200810_pre.xml EX-101.PRE 10941
7 EXTRACTED XBRL INSTANCE DOCUMENT d51957d8k_htm.xml XML 3236
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 201089277
SIC: 2834 Pharmaceutical Preparations